BioSpace News Archive

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in Immunology of positive results from a Phase 1 trial exploring intrapleural delivered Olvi-Vec in patients with malignant pleural effusion (MPE) due to either MPM or metastatic disease (non-small cell lung cancer or breast cancer).

Marker Therapeutics, Inc. (Nasdaq: MRKR) announced that zedenoleucel, its multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, was granted Orphan Drug Designation by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) for the treatment of patients with acute myeloid leukemia (AML).

Iovance Biotherapeutics, Inc. today announced positive regulatory and clinical updates related to its registrational single-arm Phase 2 IOV-LUN-202 trial in post-anti-PD-1 NSCLC.

Bio-Techne Corporation (NASDAQ:TECH) today announced it has completed the acquisition of Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions.

Novartis Pharmaceuticals Canada Inc. is pleased to announce that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) and the Institut national d’excellence en santé et services sociaux (INESSS) have recommended PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection) for public reimbursement.

Ionis Pharmaceuticals (Nasdaq: IONS) today announced positive topline, 85-week data from the Phase 3 NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Elsie Biotechnologies, Inc. announced today a research collaboration agreement with GSK plc (LSE/NYSE: GSK) to advance the discovery and development of Elsie’s innovative oligonucleotide discovery platform with the aim of finding novel oligonucleotides optimized for safety, efficacy, and delivery.

BeiGene and DualityBio today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors.

Switch Therapeutics today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.

Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), Exscientia’s precision-designed CDK7 inhibitor, for the treatment of advanced solid tumours.